Company news

Jiangsu Yahong Meditech Co., Ltd. Class A (SSE:688176) news

Jiangsu Yahong Meditech Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (688176)"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Resolutions…

Jiangsu Yahong Meditech Co., Ltd. Class A (SSE:688176) news

Press releases & updates

(688176)"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Resolutions of the Employees' Congress

(688176)"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Resolutions of the 25th Meeting of the 2nd Board of Directors

"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Summary of the 2026 Employee Stock Ownership Plan (Draft)

"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase I Clinical Trial of APL-2501

"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Change of Core Technical Personnel

"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"JIANGSU YAHONG MEDITECH CO., LTD."Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026

"Jiangsu Asieris Pharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of APLD-2304 Obtaining EU CE Certification

"Jiangsu Asieris Pharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of the Approval of the Clinical Trial Application for APL-2501 by the National Medical Products Administration

"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Voluntary Disclosure of the FDA Approval of the APL-2501 Clinical Trial Application

"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Arbitration Progress and Submission of Counter‑claim in Arbitration

"JIANGSU YAHONG MEDITECH CO., LTD."Announcement on Receipt of Arbitration Notice

Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering

Announcement on Adjustment of Key Technical Personnel

Announcement on Vesting Results of the 3rd Vesting Period of Those Initially Granted and the 2nd Vesting Period of Those Reserved for Grant in 2022 Restricted Stock Incentive Plan and Listing of Stocks

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Resignation of Securities Affairs Representative

Announcement on By-election of Directors

Announcement on Resolutions of the 22nd Meeting of the 2nd Board of Directors

Announcement on Requesting the General Meeting to Authorize the Board of Directors to Conduct Issuance of Shares to Specific Objects by Summary Procedure

Announcement on Resignation of Non-independent Director

Announcement on Abnormal Fluctuations in Stock Trading

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Announcement on Voluntary Disclosure of Successful Acceptance of the Marketing Authorization Application for APL-1702 by the European Medicines Agency

Announcement on Expected Loss in Performance for 2025

Announcement on Voluntary Disclosure of Permission Granted by the Australian Authorities for the Initiation of Phase I Clinical Trials of APL-2401

Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management

Announcement on Voluntary Disclosure of Completion of 1st Subject Enrollment in Phase 1 Clinical Trial of APL-2401

Announcement on Voluntary Disclosure of Acceptance of APLD-2304 for European Medical Device Registration

Announcement on Voluntary Disclosure of Clinical Trial Applications for APL-2401 Approved by China NMPA

Announcement on Voluntary Disclosure of the Release of APL-1401 Phase Ib Clinical Trial Data at the 19th European Colorectal Congress (ECC)

Announcement on Changing Signatory Certified Public Accountant

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Completing Changes in Registered Capital and Obtaining Renewed Business License

Announcement on Election of Employee Directors for the 2nd Board of Directors and Appointment of Senior Management Members

Announcement on Voluntary Disclosure of Publication of Relevant Data from the APL-1702 International Multicenter Phase 3 Clinical Trial in the International Journal "Med"

Announcement on Departure of Company Director and Senior Management Member

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Notice on Convening the 2nd Extraordinary General Meeting in 2025

Announcement on Canceling the Board of Supervisors, Changing the Registered Capital, Amending the "Articles of Association", Handling Industrial and Commercial Change Registration, and Formulating and Revising Some Corporate Governance Systems

Announcement on Voluntary Disclosure of Positive Preliminary Results from APL-1401 Phase Ib Clinical Trial

Announcement on Vesting Results of the 2nd Vesting Period of Those Initially Granted and the 1st Vesting Period of Those Reserved for Grant in 2022 Restricted Stock Incentive Plan and Listing of Stocks

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Notice on Convening the 1st Extraordinary General Meeting in 2025

Announcement on Listing and Circulation of Some Restricted Stocks in Initial Public Offering

Announcement on Resolution of the 12th Meeting of the 2nd Board of Supervisors

Announcement on Resolution of the 2024 Annual General Meeting

Report for Q1 2025

Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing and Q1 2025 Performance Briefing

Special Report on Deposit and Actual Use of Raised Funds in 2024